Angel Pharmaceuticals Announces Approval of IND Application for Phase 1|1b Clinical Trial of Mupadolimab (Anti-CD73) in China
JIAXING,China and BURLINGAME,Calif. , Sept. 27, 2022 |PRNewswire| -- Angel Pharmaceuticals Ltd. ("Angel Pharma"), a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1| 1b clinical trial in China . Angel Pharma owns mupadolimab''s rights in Greater China . Mupadolimab is a humanized monoclonal antibody directed against CD73 . In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. Compare with other anti-CD73 antibodies and smallmolecule drugs in development, mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses.
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1|1b Clinical Trial of Mupadolimab (Anti-CD73) in China
JIAXING,China and BURLINGAME,Calif. , Sept. 27, 2022 |PRNewswire| -- Angel Pharmaceuticals Ltd. ("Angel Pharma"), a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1| 1b clinical trial in China . Angel Pharma owns mupadolimab''s rights in Greater China . Mupadolimab is a humanized monoclonal antibody directed against CD73 . In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. Compare with other anti-CD73 antibodies and smallmolecule drugs in development, mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses.